We are data scientists and chemists, biologists and engineers, clinicians and lab managers, pharmacologists and software developers. We work across functions and employ diverse scientific languages. We work with super-resolution microscopes, living cells, algorithms and robotics — all so we can observe therapeutically relevant biology in a way no one has before.
We are endlessly curious, intellectually honest and we love what we do. We are driven to explore mechanisms of biology and pharmacology at the molecular level, and to make the biggest difference in as many lives as possible.
Eikon Therapeutics was founded on the premise that drug discovery could be dramatically improved through the visualization of protein motion at the cellular level. Our founders, Robert Tjian, Luke Lavis, Xavier Darzacq and Eric Betzig had a vision that observing and learning how putative drug targets respond to potential drug candidates might enable the invention of important new medicines. Building on the Nobel Prize-winning technology of Eric Betzig, our team has enhanced super-resolution microscopy to run at industry scale with impressive resolution, high-throughput automation and powerful AI-driven data analytics. Our interdependent, collaborative approach to drug discovery embeds researchers and engineers together in the labs to invent solutions to extremely difficult problems. Eikon is a singular company dedicated to creating new medicines through previously unimaginable technologies.